Published in Pharma Investments, Ventures and Law Weekly, July 17th, 2005
ATPotent, which is a liquid formulation of adenosine 5'-triphosphate (ATP), is being developed by Duska as a proprietary drug for the treatment of male infertility in conjunction with intrauterine insemination and in vitro fertilization.
There are approximately 6 million infertile couples seeking medical help annually in the U.S.; the male factor is at least partly responsible for the infertility in about 50% of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures and Law Weekly